Exodus Point Capital Management, LP Lineage Cell Therapeutics, Inc. Transaction History

Exodus Point Capital Management, LP

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 11, 2023	BUY	$1.2 - $1.53 $38,571 - $49,178	32,143 New	32,143 $48,000
Q1 2022 May 13, 2022	SELL	$1.21 - $2.48 $14,691 - $30,112	-12,142 Closed	0 $0
Q4 2021 Feb 11, 2022	BUY	$1.84 - $2.68 $22,341 - $32,540	12,142 New	12,142 $30,000
Q2 2021 Aug 16, 2021	SELL	$2.17 - $3.0 $725,207 - $1 Million	-334,197 Closed	0 $0
Q1 2021 May 17, 2021	SELL	$1.77 - $3.1 $837,944 - $1.47 Million	-473,415 Reduced 58.62%	334,197 $785,000
Q4 2020 Feb 16, 2021	BUY	$0.95 - $1.83 $752,490 - $1.45 Million	792,095 Added 5104.69%	807,612 $1.42 Million
Q3 2020 Nov 16, 2020	BUY	$0.75 - $1.09 $1,719 - $2,499	2,293 Added 17.34%	15,517 $15,000
Q2 2020 Aug 14, 2020	BUY	$0.71 - $1.18 $9,389 - $15,604	13,224 New	13,224 $12,000

121

94.2M

63.8K

Ticker LCTX
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 169,755,008
Market Cap $96.8M
Description
Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, develops novel cell therapies for the treatment of degenerative diseases in the United States and internationally. The company develops OpRegen, a retinal pigment epithelium cell replacement therapy, which is in Phase I/IIa clinical trial for the treatment of the dry age-re...

Get notified when there are updates to the investment portfolio of Exodus Point Capital Management, LP, based on Form 13F filings with the SEC.

Stay updated on Exodus Point Capital Management, LP with notifications on news.